WESTBURY, N.Y., March 25, 2013 /PRNewswire/ — Vasomedical, Inc. (OTC BB: VASO), announced today that it will release its financial results for the three months and year ended December 31, 2012 on Monday, April 1, 2013.
The Company will host a conference call on Monday, April 1st at 1:00 p.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO of Vasomedical, and Michael Beecher, Chief Financial Officer of Vasomedical. To dial into the conference call, please dial 1-866-393-1344 from the U.S. or 1-631-291-4669 internationally. All dial-in participants must use the following code to access the call: 26000098. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical’s website, www.vasomedical.com, and www.kcsa.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
A replay of the conference call will be available approximately two hours after completion of the live conference call at www.vasomedical.com or www.kcsa.com. To access the dial-in replay of the call, which will be available until May 1, 2013, please dial 1-855-859-2056 or 1-404-537-3406. All dial-in participants must use the following code to access the call: 26000098.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company’s website at www.vasomedical.com.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
SOURCE: Vasomedical, Inc.
Link to PR Newswire: http://www.prnewswire.com/news-releases/vasomedical-to-report-fourth-quarter-and-year-end-2012-results-on-april-1-2013-199846791.html
WESTBURY, N.Y., Dec. 10, 2012 /PRNewswire/ — Vasomedical, Inc. (“Vasomedical” or the “Company”) (OTCBB: VASO) announced today that its shares of common stock have initiated trading via the Over-the-Counter Bulletin Board (OTCBB) under the ticker symbol “VASO”.
The listing of the Company’s common stock on the OTCBB follows FINRA’s approval on December 3, 2012 of a 15c2-11 filing submitted by World Trade Financial Corporation, a market maker. For the initial 30 days of trading on the OTCBB there will not be a bid or ask displayed publicly for Vasomedical’s common stock, given that there is only one market maker during this period, per the terms of the 15c2-11 filing. After the initial 30 days of trading on the OTCBB additional market makers can begin to make a market in the Company’s stock and a bid and ask will then be available publicly for investors.
“We are excited to initiate trading of our common stock on the OTCBB, which offers our company greater exposure to the investment community. The transition to the OTCBB is part of our broader IR strategy to gain additional investor awareness of Vasomedical and we expect to benefit from increased liquidity in the trading of our shares as a result of this new listing,” said Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc.
The OTCBB is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter (OTC) securities. An OTC equity security generally is any equity that is not listed or traded on NASDAQ® or a national securities exchange. OTCBB securities include national, regional, and foreign equity issues, warrants, units, American Depositary Receipts (ADRs), and Direct Participation Programs (DPPs). The OTCBB is not an issuer listing service, market or exchange. Although the OTCBB does not have any listing requirements, to be eligible for quotation on the OTCBB, issuers must remain current in their filings with the SEC or applicable regulatory authority. Market Makers will not be permitted to begin quotation of a security whose issuer does not meet this filing requirement.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP®Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company’s website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contact:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com
SOURCE: Vasomedical, Inc.
Link to PR Newswire: http://www.prnewswire.com/news-releases/vasomedical-common-stock-commences-trading-on-the-otcbb-182811071.html
WESTBURY, N.Y., Nov. 27, 2012 /PRNewswire/ — On November 19, The American College of Cardiology Foundation and American Heart Association (ACCF/AHA) Task Force on Practice Guidelines issued its new Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. Enhanced external counterpulsation, or EECP®Therapy, a proprietary non-invasive cardiology treatment patented by Vasomedical, Inc., (“Vasomedical” or the “Company”) (OTCQB: VASO), retained the same IIb Class of Recommendation (COR) rating it received in the ACC/AHA 2002 Guideline Update for the Management of Patients with Chronic Stable Angina. EECP Therapy was also given a B rating for Level of Evidence (LOE).
According to the Guideline, a class IIb rating maintains that procedures and treatments may be considered for patients. Additional studies with broad objectives are needed and further registry data would be helpful. This classification finds that the benefits of treatments are greater than or equal to the risk of treatment.
“We believe that the 2012 Guideline clearly characterizes EECP Therapy as the gold standard of ECP treatments, since other forms of ECP treatments were not even considered for a ranking. We are pleased that this classification reinforces EECP Therapy’s position as the preeminent, non-invasive treatment for ischemic heart disease,” said Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc.
“Throughout the past decade, EECP Therapy has been offered to hundreds of thousands of patients in hundreds of treatment centers and hospitals in the Unites States. During this time, we have gathered a wealth of data from many different studies, including randomized controlled trials published in peer-reviewed journals, and have received countless testimonials for an improvement to patients’ quality of life,” continued Dr. Ma. “We believe this treatment option should be made available to a broader patient base and are continuing our communications with the ACCF and AHA task force to explore options to raise the Class of Recommendation for EECP based on more current data than referenced in the 2012 Guideline. Our responsibility is not only to support this technology, but also to champion the patient who is not receiving this therapy and its benefits. Furthermore, we have a social obligation to support healthcare cost reduction through the expanded role of EECP Therapy, which has been demonstrated in the clinical literature to reduce re-hospitalizations and emergency room visits.”
The new Guideline puts more emphasis on healthy lifestyle and medication than on invasive procedures such as bypass surgery and the percutaneous coronary intervention. Additionally, of the three available alternative treatments for ischemic heart disease, including spinal cord stimulation and transmyocardial revascularization (TMR), EECP Therapy was the only treatment that attained the same Class of Recommendation and Level of Evidence in the new Guideline as in the 2002 Guideline. The other two alternative treatments were given lower COR and/or LOE ratings than in the 2002 Guideline. EECP is now listed as the first alternative treatment for ischemic heart disease and continues to hold an equal or greater level of acceptance in this important category.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP®Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company’s website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contact:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com
SOURCE Vasomedical, Inc.
Link to PR Newswire: http://www.prnewswire.com/news-releases/vasomedicals-eecp-therapy-receives-class-iib-rating-in-the-new-accfaha-2012-clinical-guideline-for-sihd-180984021.html
WESTBURY, N.Y., Nov. 20, 2012 /PRNewswire/ — Vasomedical, Inc. (“Vasomedical”) (OTCQB: VASO) today reported its operating results for the three- and nine-month periods ended September 30, 2012.
“We reported another strong quarter of sales for our equipment segment in the third quarter. However, changes to certain sales commission milestones for 2012 compared to 2011 have resulted in a third quarter year-over-year revenue comparison that is non-reflective of our actual performance. As such, we believe that the comparison of our revenue for the nine-month periods ended September 30, 2012 and 2011 offers a more accurate representation of our sales growth. For the nine months ended September 30, 2012, the Company reported a 17.6% increase in total revenue, compared to the same period last year,” commented Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. “We will continue to pursue additional opportunities to expand our equipment segment and explore avenues to grow our sales representation business.”
For the three months ended September 30, 2012, revenue decreased 12.4% to $5.72 million, compared to $6.53 millionfor the three months ended September 30, 2011, primarily due to a decrease in commission revenues from the Sales Representation segment, resulting from a retroactive commission rate increase that was effected in the second quarter of 2012 as opposed to the third quarter in 2011. The Company had a net loss for the three months ended September 30, 2012 of $2.52 million, compared to a net income of $0.64 million for the same period in 2011. Net loss attributable to common stockholders for the three months ended September 30, 2012 was $2.52 million or $0.02 per common share, compared to a net loss of $1.12 million or $0.01 per common share for the three months ended September 30, 2011.
The Company reported an increase in revenue of 17.6% to $19.46 million for the nine months ended September 30, 2012, compared to revenue of $16.55 million for the same period in 2011. The increase in revenue is the result of improved performance in all areas of the Company’s business, including sales of EECP® Therapy systems and its operations in China, as well as increased commission revenue from VasoHealthcare. For the nine months ended September 30, 2012, the Company reported a net loss of $3.81 million compared to a net loss of $1.36 million for the same period in 2011. The losses were principally due to an increase of costs related to an extension of the sales representation agreement with GE Healthcare, as well as increased sales and marketing costs for the Equipment segment. The costs for the Equipment segment now includes SG&A costs of the recently acquired Chinese entities and one-time costs incurred for incentive compensation for certain key employees. For the nine months ended September 30, 2012, the Company had a net loss attributable to common stockholders of $3.81 million or $0.02 per common share, compared to a net loss applicable to common stockholders of $2.82 million or $0.02 per common share for the nine months ended September 30, 2011.
The Company continues to record a substantial amount of deferred revenues, which will be recognized once the underlying equipment or service is accepted by the customer or performed by the Company. As of September 30, 2012, total deferred revenues were approximately $14.99 million, and the Company reported cash and cash equivalents of approximately $9.69 million.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain markets. Additional information is available on the Company’s website at www.vasomedical.com.
|
Summarized Financial Information |
|||||
|
FOR THE THREE MONTHS ENDED |
FOR THE NINE MONTHS ENDED |
||||
|
STATEMENTS OF OPERATIONS |
September 30, 2012 |
September 30, 2011 |
September 30, 2012 |
September 30, 2011 |
|
|
(In thousands except per share amounts) |
|||||
|
Revenue |
$5,722 |
$6,530 |
$19,462 |
$16,549 |
|
|
Gross profit |
$4,063 |
$4,719 |
$13,774 |
$11,462 |
|
|
Operating (loss) income |
$(2,659) |
$26 |
$(3,885) |
$(1,417) |
|
|
Other income (expense), net |
$97 |
$43 |
$151 |
$63 |
|
|
(Loss) income before taxes |
$(2,562) |
$69 |
$(3,734) |
$(1,354) |
|
|
Income tax benefit (expense) |
$44 |
$(5) |
$(72) |
$(4) |
|
|
Net (loss) income |
$(2,518) |
$64 |
$(3,806) |
$(1,358) |
|
|
Preferred stock dividends |
$ – |
$(1,180) |
$ – |
$(1,459) |
|
|
Net (loss) income applicable to common stockholders |
$(2,518) |
$(1,116) |
$(3,806) |
$(2,817) |
|
|
BALANCE SHEETS |
September 30, 2012 |
December 31, 2011 |
|||
|
(In thousands) |
|||||
|
Total current assets |
$23,856 |
$28,500 |
|||
|
Total assets |
$29,509 |
$34,335 |
|||
|
Total current liabilities |
$16,125 |
$17,175 |
|||
|
Total stockholders’ equity |
$8,361 |
$11,276 |
|||
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com
SOURCE: Vasomedical, Inc.
Link to PR Newswire: http://www.prnewswire.com/news-releases/vasomedical-announces-financial-results-for-the-third-quarter-of-2012-180144661.html
WESTBURY, N.Y., Nov. 15, 2012 /PRNewswire/ — Vasomedical, Inc. (“Vasomedical”) (OTCQB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP® systems, the gold standard of ECP therapy, announced today that it was named to Deloitte’s Technology Fast 500™, a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.
The Deloitte Technology Fast 500™ are selected based on percentage fiscal year revenue growth from 2007 to 2011. Vasomedical’s revenue grew 158 percent during the period.
“We are honored to be included in Deloitte’s prestigious Technology Fast 500 list of companies for 2012,” said Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. “Our inclusion in this exciting group highlights the development our Company has been experiencing as we continue to implement our growth strategy, which includes product and business diversification, as well as strong support from medical providers of our EECP Therapy, a non-invasive heart disease treatment.”
Vasomedical will appear on the Technology Fast 500™ list on www.fast500.com.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP®Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company’s website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
About Deloitte’s 2012 Technology Fast 500™
Technology Fast 500, conducted by Deloitte & Touche LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private – in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2007 to 2011.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1215 / 212-896-1250
Email: tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
Phone: 212-896-1216 / 212-896-1220
Email: lgoldberg@kcsa.com / swolf@kcsa.com
SOURCE: Vasomedical, Inc.
Link to PR Newswire: http://www.prnewswire.com/news-releases/vasomedical-named-on-deloittes-2012-technology-fast-500-list-179475651.html
© 2025 Vaso Corporation | Terms of Service | Privacy Policy
